Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/4/2017
SIETES contiene 91761 citas

 
 
 1 a 20 de 1106 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
2.Enlace a cita originalTiene citas relacionadas
Valente M, Bhandari S. Renal function after new treatment with renin-angiotensin system blockers. BMJ 2017;356:j1122. [Ref.ID 101474]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, Sørensen HT, Smeeth L, Tomlinson LA. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 2017;356:j791. [Ref.ID 101473]
4. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
5.Tiene citas relacionadas Cita con resumen
Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med 2017;177:67-76. [Ref.ID 101344]
6.Enlace a cita original
Pfeffer MA, McMurray JJV. Lessons in uncertainty and humility — Clinical trials involving hypertension. N Engl J Med 2016;375:1756-66. [Ref.ID 100966]
8.Tiene citas relacionadas Cita con resumen
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-75. [Ref.ID 100609]
9.Tiene citas relacionadas Cita con resumen
Anónimo. Atrial fibrillation and stroke: unrecognised and undertreated. Lancet 2016;388:731. [Ref.ID 100608]
10. Cita con resumen
Whittle J. Blood pressure variability and cardiovascular risk. BMJ 2016;354:i4190. [Ref.ID 100604]
11. Cita con resumen
Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, McManus RJ. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ 2016;354:i4098. [Ref.ID 100603]
12. Cita con resumen
Mente A, O’Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R, Mony P, Yusuf R, Yusoff K, Szuba A, Oguz A, Rosengren A, Bahonar A, Yusufali A, Schutte AE, Chifamba J, Mann JFE, Anand SS, Teo K, Yusuf S, for the PURE EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 2016;388:465-85. [Ref.ID 100513]
13. Cita con resumen
O'Brien E. Salt—too much or too little?. Lancet 2016;388:439-40. [Ref.ID 100512]
14. Cita con resumen
15.Tiene citas relacionadas Cita con resumen
Cunningham CJ. Research into “real world” older patients is needed. BMJ 2016;353:i3136. [Ref.ID 100379]
16.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
17.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
18.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
19.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
20. Cita con resumen
Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]
Seleccionar todas
 
 1 a 20 de 1106 siguiente >>